Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCTs061230013
JPRN-jRCTs061230013
Recruiting
Phase 2

A phase II study to examine the efficacy and safety of tranilast for trigeminal neuralgia

Ikutame Daisuke0 sites15 target enrollmentMay 12, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsTrigeminal neuralgiaTrigeminal neuropathic painTrigeminal Neuralgia

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Trigeminal neuralgia
Sponsor
Ikutame Daisuke
Enrollment
15
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ikutame Daisuke

Eligibility Criteria

Inclusion Criteria

  • •Patients who visit Tokushima University Hospital's Department of Fixed Prosthodontics, Temporomandibular Disorder Clinic, Department of Dental Anesthesiology
  • •Patients diagnosed with trigeminal neuralgia according to the International Classification of Orofacial Pain
  • •Patients aged 50 to 80

Exclusion Criteria

  • •Patients with secondary trigeminal neuralgia who find organic changes in the brain by CT or MRI, patients taking warfarin, patients planning to move, pregnant women (especially within about 3 months) or possibly pregnant, patients deemed inappropriate by the principal investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
A phase 2 study of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapies
CTIS2022-503041-21-00ovartis Pharma AG40
Recruiting
Not Applicable
A phase 2 study to evaluate the efficacy and safety of temozolomide in advanced gastrointestinal stromal tumor patients with SDH deficiency
KCT0008244Asan Medical Center29
Unknown
Phase 2
A phase 2 study of K-134 in patients with intermittent claudicatioPeripheral arterial disease
JPRN-jRCT2080221661Kowa Co., Ltd.330
Active, not recruiting
Not Applicable
A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combination with lapatinib for metastatic diseasemetastatic breast cancer
EUCTR2009-016826-15-ATCECOG30
Active, not recruiting
Phase 1
A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients pretreated with chemotherapy or hormonal treatment in combination with lapatinib for metastatic diseasemetastatic breast cancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2009-016826-15-CZCECOG30